Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment

Neurotoxicity Research

Volumn 5, Issue 1-2, 2003, Pages 95-109

  Archer, Trevor ^a   Palomo, Tomas ^b   McArthur, Robert ^c   Fredriksson, Anders ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c PFIZER INC   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

7 OH DPAT; Apomorphine; Bromocriptine; C57Bl 6 mice; Cabergoline; FCE 23884; Locomotion; MPTP; Neonatal 6 OHDA; Quinpirole; SKF 38393; Wistar rats

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; OXIDOPAMINE;

ANIMAL; ARTICLE; BRAIN LEVEL; C57BL MOUSE; DENERVATION; DRUG EFFECT; DRUG INTERACTION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; NEWBORN; RAT; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; BRAIN CHEMISTRY; DENERVATION; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG INTERACTIONS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OXIDOPAMINE; RATS; RATS, WISTAR; SYMPATHOLYTICS;

EID: 0642345899     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033375     Document Type: Article

References (71)

1. Arai N, M Isaji, H Miyata, E Mizuza and S Kuno (1994) Effects of cabergoline on experimental parkinsonism in MPTP-treated monkeys. Japan. J. Pharmacol. 64, 172.
2. Archer T and A Fredriksson (1992) Functional changes implicating dopaminergic systems following perinatal treatments. Dev. Pharmacol. Ther. 18, 201-222.
3. Archer T, A Fredriksson, G Jonsson, T Lewander, AK Mohammed, SB Ross and U Söderberg (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology (Berl), 88, 141-146.
4. Ariano MA (1989) Long-term changes in striatal D-1 dopamine receptor distribution after dopaminergic deafferentiation. Neuroscience 32, 203-212.
5. 2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Movem. Dis. 9, 147-154.
6. Bhatt MH, SP KeenanP, JA Fleetham and DB Calne (1991) Pleuropulmonary disease associated with dopamine agonist therapy. Ann. Neurol. 30, 613-616.
7. Bjork L, LJ Cornfield, DL Nelson, SE Hillver, NE Anden, T Lewander and U Hacksell (1991) Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: Inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J. Pharmacol. Exp. Ther. 258, 58-65.
8. Booth RG, RJ Baldessarini, E Marsh and CE Owens (1994) Actions of (+/ -)-7-hydroxy- N,N -dipropylaminotetralin (7-OH-DPAT) on dopamine synthesis in limbic and extrapyramidal regions of rat brain. Brain Res. 662, 283-288.
9. Buonamici M, C Caccia, M Carpentieri, L Pegrassi, AC Rossi and G Di Chiara (1986) D-1 receptor supersentitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 126, 347-348.
10. Davis GC, AC Williams, SP Markey, MH Ebert, ED Caine, CM Reichert and IJ Kopin (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr. Res. 1, 249-254.
11. Di Chiara G, ML Porceddu, L Vargui, E Stefanini and GL Gessa (1977) Evidence for selective and long-lasting stimulation of "regulatory" dopamine-receptors by bromocriptine (CB-154). Naunyn-Schmiedeberg's Arch. Pharmacol. 300, 239-245.
12. Ferrari C, C Barbieri, R Caldara, M Mucci, F Codecasa, A Paracchi, C Romano, M Boghen and A Dubini (1986) Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63, 941-946.
13. Fredriksson A and T Archer (1994) MPTP-induced behavioural and biochemical deficits: A paramatric analysis. J. Neural Transm. 7, 123-132.
14. Fredriksson A, A Plaznik, E Sundström, G Jonsson and T Archer (1990) MPTP-induced hypoactivity in mice: Reversal by L-dopa. Pharmacol. Toxicol. 67, 295-301.
15. Fredriksson A, M Bassen, MA Cervini, CP Post, T Archer and R McArthur (1996) Effects of dopamine agonists upon locomotor function in denervated mice and rats: Comparison with cabergoline, In: Beninger RJ, T Palomo and T Archer, Eds, Dopamine Disease States (Madrid University Press, Madrid), pp 141-167.
16. Fuxe K, BB Fredholm, LF Agnati, SO Ögren, BJ Everitt, G Jonsson and JÅ Gustafsson (1978a) Interaction of ergot drugs with central monoamine systems: Evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology, 16(Suppl. 1), 99-134.
17. Fuxe K, BB Fredholm, SO Ögren, LF Agnati, T Hökfelt and JÅ Gustafsson (1978b) Ergot drugs and central monoaminergic mechanisms: A histochemical, biochemical and behavioural analysis. Fed. Proc. 37, 2181-2191. 2181-2191.
18. Gagnon C, PF Bedard and T Di Paoli (1990) Effect of chronic treatment of MPTP monkeys with dopamine D-1 and D-2 receptor agoists. Eur. J. Pharmacol. 178, 115-120.
19. Gancher ST, WR Woodward, B Boucher and JG Nutt (1989) Peripheral pharmarmacokinetics of apomorphine in humans. Ann. Neurol. 26, 232-238.
20. 3 receptors in rat brain. Eur. J. Pharmacol. 211, 189-194.
21. Goetz CG (1990) Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 40, 50-71.
22. Goetz CG and NJ Diederich (1992) Dopaminergic agonists in the treatment of Parkinson's disease. Neurol. Clin. 10, 527-540.
23. 2 receptor agonist reduces L-DOPA-induced dyskinesia in MPTP monkeys. Can. J. Physiol. Pharmacol. 72(Suppl. 1), 385.
24. Hahn RA, BR MacDonald and MA Martin (1983) Antihypertensive effects of LY 141865, a selective presynaptic dopamine receptor agonist. J. Pharmacol. Exp. Ther. 224, 206-213.
25. Heikkila RE, A Hess and RC Duvoisin (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on neostriatal dopamine in mice. Science, 224, 1451-1453.
26. Heikkila RE, B-A Sieber, L Manzino and PK Sonsalla (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropathol. 10, 171-183.
27. Hutton JT, JL Morris and AB Melanie (1993) Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 43, 613-618.
28. Irifune M, M Nomoto and T Fukuda (1994) Antiparkinsonian activity of talipexole in MPTP-treated monkeys: In combination with L-Dopa and as chronic treatment. Eur. J. Pharmacol. 264, 117-123.
29. Jackson DM and M Hashizume (1986) Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF 38393. Psychopharmacology 90, 147-149.
30. Jackson DM and M Hashizume (1987) Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors. J. Neural Transm. 69, 131-145.
31. Jackson DM, OF Jenkins and SB Ross (1988) The motor effects of bromocriptine-review. Psychopharmacology 95, 433-446.
32. Jackson DM, JA Watson and SB Ross (1994) The peculiar pharmacology of bromocriptine. In: Palomo T, T Archer and RJ Beninger, Eds, Strategies for Studying Brain Disorders: Schizophrenia, Movement Disorders and Age Related Cognitive Disorders ((Madrid University Press, Madrid), pp 189-199.
33. Kebabian JW and DB Calne (1979) Multiple receptors for dopamine. Nature 277, 93-96.
34. Kirk R (1995) Experimental design: Procedures for the behavioural sciences. Brooks/Cole, Belmont, CA.
35. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19, 1-17.
36. Kostrzewa RM (2003) Dopamine receptor supersensitivity: An outcome and index of neurotoxicity. Neurotoxicity Res. 5, 111-118.
37. 3 receptor agonist 7-OH-DPAT in thesus monkeys trained to discriminate cocaine from saline. Psychopharmacology 124, 306-314.
38. Langston JW, P Ballard, JW Tetrud and I Irwin (1983) Chronic parkinsonism in humans due to a product of meperidine-analogue synthesis. Science, 219, 979-980.
39. Lera G, J Vaamonde, M Rodriguez and JA Obeso (1993) Cabergoline in Parkinson's disease: Long-term follow-up. Neurology 43, 2587-2590.
40. Liberini P, S Parola, PF Spano and L Antonini (2000) Olfaction in Parkinson's disease: Methods of assessment and clinical relevance. J. Neurol. 247, 88-96.
41. Lieberman A, T Miyamoto, A Battista and M Goldstein (1975) Studies on the antiparkinsonian efficacy of lergotrile. Neurology 25, 459-462.
42. Lieberman A, M Zolfaghari, D Boal, H Hassouri, B Vogel, A Battista, K Fuxe and M Goldstein (1976) The antiparkinson efficacy of bromocriptine. Neurology 26, 405-409.
43. Lieberman A, M Goldstein, G Gopinathan and A Neophytides (1987) D-1 and D-2 agonists in Parkinson's disease. Can. J. Neurol. Sci. 14, 466-473.
44. Lieberman A, S Imke, M Muenter, K Wheeler, JE Ahlskog, JY Matsumoto, DM Maraganore, KF Wright and J Schoenfelder (1993) Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 43, 1981-1984.
45. 2-receptor antagonists. J. Med. Chem. 38, 150-160.
46. Loew DM, J-M Vigouret and AL Jaton (1976) Neuropharmacological investigations with two ergot alkaloids, hydergine and bromocriptine. Postgrad. Med. J. 52(Suppl. 1), 40-46.
47. Longoni R, L Spina and G Di Chiara (1987) Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioural responses: A quantitative phenomenological study in rats. Life Sci. 41, 2135-2145.
48. Luthman J, A Fredriksson, E Sundström, G Jonsson and T Archer (1989a) Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: Motor behaviour and monoamine alterations at adult stage. Brain Res. 33, 267-277.
49. Luthman J, A Fredriksson, T Lewander, G Jonsson and T Archer (1989b) Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology 99, 550-557.
50. Luthman J, A Fredriksson, A Plaznik and T Archer (1991) Ketanserin or mianserin treatment reverses hyperactivity in neonatally dopamine lesioned rats. J. Psychopharmacol. 5, 418-425.
51. Luthman J, M Bassen, A Fredriksson and T Archer (1997) Functional changes induced by neonatal 6-hydroxydopamine lesions: Effects of dose levels on behavioural parameters. Behav. Brain Res. 82, 213-221.
52. 2 agonist, on reserpine-treated rodents. Biol. Pharm. Bull. 19, 1499-1502.
53. Miyagi M, F Itoh, F Taya, N Arai, M Isaji, M Kojima and A Ujiie (1996b) Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biol. Pharm. Bull. 19, 1210-1213.
54. 3 receptors. Eur. J. Pharmacol. 366, 293-300.
55. Pfitzenmeyer P, P Foucher, G Dennewald, B Chevalon, D Debieuvre, P Bensa, F Piard and P Camus (1996) Pleuropulmonary changes induced by ergoline drugs. Eur. Respir. J. 9, 1013-1019.
56. Rinne U K (1989) Combination of a dopamine agonist, MAO-B inhibitor and levodopa - a new strategy in the treatment of early Parkinson's disease. Acta Neurol. Scand. Suppl. 126, 165-169.
57. Roehrich H, CA Dackis and MS Gold (1987) Bromocriptine. Med. Res. Rev. 7, 243-269.
58. Rolland R, G Piscitelli, C Ferrari and A Petroccione (1991) Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. Brit. Med. J. 302, 1367-1371.
59. 2 agonists in squirrel monkeys. Psychopharmacology 116, 9-18.
60. 2 receptor activation. Life Sci. 40, 2461-2471.
61. 1 receptor pharmacology. ISI Atlas Sci. Pharmacol. 2, 161-169.
62. Silbergeld EK, RE Hruska, R Weir and SW Kennedy (1979) Dopaminergic and serotonergic effects of ergot drugs, In: K Fuxe and DB Calne, Eds, Dopaminergic Ergot Derivatives and Motor Function, (Pergamon Press, Oxford) pp 223-235.
63. 2 receptor. Eur. J. Pharmacol. 225, 331-337.
64. Sonsalla PK and RE Heikkila (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129, 339-345.
65. 3H] N-n-propylnorapomorphine. Eur. J. Pharmacol. 187, 399-404.
66. Sundström E, A Fredriksson and T Archer (1990) Chronic neurochemical and behavioural changes in MPTP-lesioned C57 BL/6 mice: A model for Parkinson's disease. Brain Res. 528, 181-188.
67. Trugman JM and GF Wooten (1987) Selective D-1 and D-2 dopamine agonists deferentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J. Neurosci. 7, 2927-2935.
68. Weihmüller FB, M Hadjiconstantinou and JP Bruno (1989) Dissociation between the biochemical and behavioural recovery in MPTP-treated mice. Pharmacol. Biochem. Behav. 34, 113-117.
69. 2 agonist LY 171555 act synergistically to stimulate motor behaviour of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Movem. Dis. 9, 664-672.
70. 123I]IBZM as measured with SPECT in MPTP monkeys. Synapse 17, 115-124.
71. Yurek DM and SB Hipkens (1994) Intranigral injections of SCH 23390 inhibit SKF 82958-induced rotational behavior. Brain Res. 639, 329-332.